ALKS
Price
$29.05
Change
+$0.79 (+2.80%)
Updated
Aug 15 closing price
Capitalization
4.8B
66 days until earnings call
EOLS
Price
$6.73
Change
+$0.33 (+5.16%)
Updated
Aug 15 closing price
Capitalization
435.33M
86 days until earnings call
Interact to see
Advertisement

ALKS vs EOLS

Header iconALKS vs EOLS Comparison
Open Charts ALKS vs EOLSBanner chart's image
Alkermes
Price$29.05
Change+$0.79 (+2.80%)
Volume$1.59M
Capitalization4.8B
Evolus
Price$6.73
Change+$0.33 (+5.16%)
Volume$1.07M
Capitalization435.33M
ALKS vs EOLS Comparison Chart in %
Loading...
ALKS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EOLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALKS vs. EOLS commentary
Aug 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALKS is a Hold and EOLS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 17, 2025
Stock price -- (ALKS: $29.05 vs. EOLS: $6.73)
Brand notoriety: ALKS and EOLS are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ALKS: 87% vs. EOLS: 71%
Market capitalization -- ALKS: $4.8B vs. EOLS: $435.33M
ALKS [@Pharmaceuticals: Generic] is valued at $4.8B. EOLS’s [@Pharmaceuticals: Generic] market capitalization is $435.33M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.3B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.75B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALKS’s FA Score shows that 1 FA rating(s) are green whileEOLS’s FA Score has 0 green FA rating(s).

  • ALKS’s FA Score: 1 green, 4 red.
  • EOLS’s FA Score: 0 green, 5 red.
According to our system of comparison, ALKS is a better buy in the long-term than EOLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALKS’s TA Score shows that 5 TA indicator(s) are bullish while EOLS’s TA Score has 4 bullish TA indicator(s).

  • ALKS’s TA Score: 5 bullish, 4 bearish.
  • EOLS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ALKS is a better buy in the short-term than EOLS.

Price Growth

ALKS (@Pharmaceuticals: Generic) experienced а +8.76% price change this week, while EOLS (@Pharmaceuticals: Generic) price change was +14.07% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +4.25%. For the same industry, the average monthly price growth was +10.98%, and the average quarterly price growth was +78.05%.

Reported Earning Dates

ALKS is expected to report earnings on Oct 22, 2025.

EOLS is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+4.25% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALKS($4.8B) has a higher market cap than EOLS($435M). ALKS YTD gains are higher at: 1.008 vs. EOLS (-39.040). ALKS has higher annual earnings (EBITDA): 450M vs. EOLS (-30.78M). ALKS has more cash in the bank: 1.02B vs. EOLS (67.9M). ALKS has less debt than EOLS: ALKS (72.7M) vs EOLS (130M). ALKS has higher revenues than EOLS: ALKS (1.51B) vs EOLS (275M).
ALKSEOLSALKS / EOLS
Capitalization4.8B435M1,103%
EBITDA450M-30.78M-1,462%
Gain YTD1.008-39.040-3%
P/E Ratio14.03N/A-
Revenue1.51B275M547%
Total Cash1.02B67.9M1,496%
Total Debt72.7M130M56%
FUNDAMENTALS RATINGS
ALKS vs EOLS: Fundamental Ratings
ALKS
EOLS
OUTLOOK RATING
1..100
2851
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
92
Overvalued
PROFIT vs RISK RATING
1..100
4176
SMR RATING
1..100
40100
PRICE GROWTH RATING
1..100
6194
P/E GROWTH RATING
1..100
30100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EOLS's Valuation (92) in the Pharmaceuticals Major industry is in the same range as ALKS (97) in the Biotechnology industry. This means that EOLS’s stock grew similarly to ALKS’s over the last 12 months.

ALKS's Profit vs Risk Rating (41) in the Biotechnology industry is somewhat better than the same rating for EOLS (76) in the Pharmaceuticals Major industry. This means that ALKS’s stock grew somewhat faster than EOLS’s over the last 12 months.

ALKS's SMR Rating (40) in the Biotechnology industry is somewhat better than the same rating for EOLS (100) in the Pharmaceuticals Major industry. This means that ALKS’s stock grew somewhat faster than EOLS’s over the last 12 months.

ALKS's Price Growth Rating (61) in the Biotechnology industry is somewhat better than the same rating for EOLS (94) in the Pharmaceuticals Major industry. This means that ALKS’s stock grew somewhat faster than EOLS’s over the last 12 months.

ALKS's P/E Growth Rating (30) in the Biotechnology industry is significantly better than the same rating for EOLS (100) in the Pharmaceuticals Major industry. This means that ALKS’s stock grew significantly faster than EOLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALKSEOLS
RSI
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
65%
Bullish Trend 3 days ago
78%
Momentum
ODDS (%)
Bullish Trend 3 days ago
75%
Bearish Trend 3 days ago
79%
MACD
ODDS (%)
Bullish Trend 3 days ago
70%
Bearish Trend 3 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
82%
Advances
ODDS (%)
Bullish Trend 5 days ago
75%
Bullish Trend 5 days ago
79%
Declines
ODDS (%)
Bearish Trend 12 days ago
63%
Bearish Trend 7 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
67%
Bullish Trend 3 days ago
74%
Aroon
ODDS (%)
Bearish Trend 3 days ago
57%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ALKS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EOLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BGESX14.400.12
+0.84%
Baillie Gifford International Growth I
MFVZX17.64N/A
N/A
MassMutual Equity Opports I
TRSAX111.75-0.09
-0.08%
T. Rowe Price Growth Stock Adv
LBISX21.83-0.12
-0.55%
BrandywineGLOBAL Div US Large Value IS
DBMZX30.39-0.21
-0.69%
BNY Mellon Sm/Md Cp Gr Z

EOLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EOLS has been loosely correlated with PRGO. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if EOLS jumps, then PRGO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EOLS
1D Price
Change %
EOLS100%
+5.16%
PRGO - EOLS
43%
Loosely correlated
-1.43%
LNTH - EOLS
33%
Loosely correlated
-0.53%
AMRX - EOLS
33%
Loosely correlated
+0.64%
ALKS - EOLS
31%
Poorly correlated
+2.80%
HROW - EOLS
28%
Poorly correlated
-2.97%
More